These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 15643273

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Antitumor effect of vaccinia virus in glioma model.
    Timiryasova TM, Li J, Chen B, Chong D, Langridge WH, Gridley DS, Fodor I.
    Oncol Res; 1999; 11(3):133-44. PubMed ID: 10527073
    [Abstract] [Full Text] [Related]

  • 4. Replication-deficient vaccinia virus gene therpay vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells.
    Timiryasova TM, Chen B, Fodor I.
    J Gene Med; 2001; 3(5):468-77. PubMed ID: 11601760
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model.
    Siemens DR, Crist S, Austin JC, Tartaglia J, Ratliff T.
    J Urol; 2003 Sep; 170(3):979-84. PubMed ID: 12913754
    [Abstract] [Full Text] [Related]

  • 7. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
    Olbert PJ, Schrader AJ, Simon C, Dalpke A, Barth P, Hofmann R, Hegele A.
    Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
    [Abstract] [Full Text] [Related]

  • 8. Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
    Kikuchi E, Menendez S, Ozu C, Ohori M, Cordon-Cardo C, Logg CR, Kasahara N, Bochner BH.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4511-8. PubMed ID: 17671137
    [Abstract] [Full Text] [Related]

  • 9. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
    Dasgupta S, Bhattacharya-Chatterjee M, O'Malley BW, Chatterjee SK.
    Mol Ther; 2006 Jan 01; 13(1):183-93. PubMed ID: 16125469
    [Abstract] [Full Text] [Related]

  • 10. Nonviral cytokine gene therapy on an orthotopic bladder cancer model.
    Wu Q, Mahendran R, Esuvaranathan K.
    Clin Cancer Res; 2003 Oct 01; 9(12):4522-8. PubMed ID: 14555526
    [Abstract] [Full Text] [Related]

  • 11. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model.
    Horiguchi Y, Larchian WA, Kaplinsky R, Fair WR, Heston WD.
    Gene Ther; 2000 May 01; 7(10):844-51. PubMed ID: 10845722
    [Abstract] [Full Text] [Related]

  • 12. In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-1beta.
    Peplinski GR, Tsung AK, Casey MJ, Meko JB, Fredrickson TN, Buller RM, Norton JA.
    Cancer J Sci Am; 1996 May 01; 2(1):21-7. PubMed ID: 9166494
    [Abstract] [Full Text] [Related]

  • 13. Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression.
    Qin H, Valentino J, Manna S, Tripathi PK, Bhattacharya-Chatterjee M, Foon KA, O'Malley BW, Chatterjee SK.
    Mol Ther; 2001 Dec 01; 4(6):551-8. PubMed ID: 11735339
    [Abstract] [Full Text] [Related]

  • 14. Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer.
    Loskog A, Björkland A, Brown MP, Korsgren O, Malmström PU, Tötterman TH.
    J Urol; 2001 Sep 01; 166(3):1093-7. PubMed ID: 11490305
    [Abstract] [Full Text] [Related]

  • 15. Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors.
    Lee SS, Eisenlohr LC, McCue PA, Mastrangelo MJ, Lattime EC.
    Cancer Res; 1994 Jul 01; 54(13):3325-8. PubMed ID: 8012943
    [Abstract] [Full Text] [Related]

  • 16. Non-viral tumor necrosis factor-alpha gene transfer decreases the incidence of orthotopic bladder tumors.
    Zang Z, Mahendran R, Wu Q, Yong T, Esuvaranathan K.
    Int J Mol Med; 2004 Oct 01; 14(4):713-7. PubMed ID: 15375606
    [Abstract] [Full Text] [Related]

  • 17. Construction of recombinant vaccinia virus expressing GM-CSF and its use as tumor vaccine.
    Qin HX, Chatterjee SK.
    Gene Ther; 1996 Jan 01; 3(1):59-66. PubMed ID: 8929912
    [Abstract] [Full Text] [Related]

  • 18. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model.
    Loskog AS, Fransson ME, Totterman TT.
    Clin Cancer Res; 2005 Dec 15; 11(24 Pt 1):8816-21. PubMed ID: 16361570
    [Abstract] [Full Text] [Related]

  • 19. Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53.
    Odin L, Favrot M, Poujol D, Michot JP, Moingeon P, Tartaglia J, Puisieux I.
    Cancer Gene Ther; 2001 Feb 15; 8(2):87-98. PubMed ID: 11263530
    [Abstract] [Full Text] [Related]

  • 20. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.
    Hadaschik BA, Zhang K, So AI, Fazli L, Jia W, Bell JC, Gleave ME, Rennie PS.
    Cancer Res; 2008 Jun 15; 68(12):4506-10. PubMed ID: 18559493
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.